Home/Pipeline/ePORE® Therapy

ePORE® Therapy

Gastrointestinal Cancers and Pre-cancerous Lesions

Pre-clinical/ClinicalActive

Key Facts

Indication
Gastrointestinal Cancers and Pre-cancerous Lesions
Phase
Pre-clinical/Clinical
Status
Active
Company

About Mirai Medical

Mirai Medical, founded in 2019 and based in Galway, Ireland, is developing the ePORE® therapy, a platform utilizing pulsed electric fields (PEF) for the endoscopic ablation of tissue, targeting gastrointestinal and skin cancers. The technology aims to offer a precise, non-thermal treatment that could reduce procedure times and complications compared to existing standards. As a private, likely pre-revenue entity, the company is in the clinical development and regulatory approval stage, positioning itself in the growing interventional endoscopy market. Its success hinges on clinical validation, regulatory clearance, and commercial execution in a competitive landscape.

View full company profile

About Mirai Medical

Mirai Medical, founded in 2019 and based in Galway, Ireland, is developing the ePORE® therapy, a platform utilizing pulsed electric fields (PEF) for the endoscopic ablation of tissue, targeting gastrointestinal and skin cancers. The technology aims to offer a precise, non-thermal treatment that could reduce procedure times and complications compared to existing standards. As a private, likely pre-revenue entity, the company is in the clinical development and regulatory approval stage, positioning itself in the growing interventional endoscopy market. Its success hinges on clinical validation, regulatory clearance, and commercial execution in a competitive landscape.

View full company profile

Therapeutic Areas